Abstract: Objective To systematically review the diagnostic value of transrectal contrast-enhanced ultrasound -guided biopsy for prostate cancer. Methods By searching PubMed, CNKI, Cochrane library and Wanfang database from establishment to 3 September 2018, all of the eligible articles about diagnosis prostate cancer with transrectal contrast-enhanced ultrasound -guided biopsy which conformed to the inclusion and exclusion criteria were harvested. The diagnostic test accuracy evaluation tool (QUADAS) was used to evaluate the quality of the included literature. The Meta-Disc 1.4 software performs heterogeneity testing and analysis on its sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio, and plots the receiver operating characteristic (SROC) curve. Results A total of 20articles, 1997 cases were analyzed in this study. The pooled sensitivity, specificity, positive likelihood radio, negative likelihood ratio and diagnostic odds ratio of transrectal contrast-enhanced ultrasound -guided biopsy for prostate cancer were 0.77 [95%CI (0.74, 0.80)], 0.81 [95%CI (0.79, 0.84,)], 4.53 [95%CI (3.30, 6.22)], 0.29 [95%CI (0.24, 0.35)], 16.94 [95%CI (10.86, 26.43)], respectively. The AUC and Q* were 0.8620 and 0.7926. Conclusions Transrectal contrast-enhanced ultrasound -guided biopsy has a good diagnostic value of prostate cancer.